Elizabeth Hamilton

1 month ago | cherwell.org | Elizabeth Hamilton

The UK and the European Union have reached a new agreement setting out post-Brexit relations on areas including fishing rights, trade and defence. For students, the main point of interest was the EU’s proposed “youth mobility scheme” for 18- to 30-year-olds, which would allow stays of up to four years without a visa.

1 month ago | cherwell.org | Elizabeth Hamilton

A door at Trinity College designed by acclaimed sculptor Antony Gormley in collaboration with UK Poet Laureate Simon Armitage has been dedicated to physicist Henry Moseley. The artwork forms part of the redevelopment of the College and its new Levine Building on site. Moseley, who earned his bachelor’s degree from Trinity in 1910, conducted research to establish the concept of the atomic number.

Feb 5, 2025 | coloradoexpression.com | Elizabeth Hamilton

As we hop into spring in Colorado, the days are getting longer—which gets me excited to plan a few trips, refocus on my wellness, refresh my interiors and start looking at spring and summer styles. This issue is all about travel, wellness and interior style, and I hope you enjoy reading it as much as we’ve enjoyed putting it together. Not to miss: Austria’s 60th anniversary celebration of The Sound of Music and the sights and sounds of that gorgeous country.

Jan 25, 2025 | ncronline.org | Elizabeth Hamilton |Bret Anthony Johnston

In 1993, U.S. federal and Texas state law enforcement agencies used battle tanks, surveillance aircraft and Black Hawk helicopters to lay siege on the Branch Davidian religious compound located on a rudimentary ranch just northeast of Waco, Texas.

Oct 29, 2024 | friedreichsataxianews.com | Marisa Wexler |Elizabeth Hamilton |Lindsey Shapiro |Steve Bryson

PTC Therapeutics says it’s planning, this December, to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy vatiquinone — which has been tested in pediatric patients as well as adults — as a treatment for Friedreich’s ataxia (FA). “We look forward to submitting the NDA [new drug application] by the end of the year,” Matthew B. Klein, MD, PTC’s CEO, said in a company press release.